Kidney Diseases, Chronic
7
2
2
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
29%
2 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (7)
Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
Rutgers University Study of the Genetics of Kidney Disease
Anrikefon vs Nalfurafine for Sleep Quality in Hemodialysis Patients With CKD-aP
The Predictive Capacity of Machine Learning Models for Progressive Kidney Disease in Individuals With Sickle Cell Anemia
The Effect Of Mobile Traınıng Applıcatıons On Chronıc Renal Faılure Progressıon
A Pilot Feasibility Trial of Thyroid Hormone Replacement in Dialysis Patients
Metabolomics for Identifying Biomarkers of Dietary Intake and Kidney Disease Progression